


S1P Pathway Mutations Associate with Disease Stage in DLBCL

Retention pathway effect strongest in GCB (Schmitz); Egress pathway effect in pan-DLBCL (Duke); DFCI underpowered


A. Schmitz 2018: GCB-DLBCL

EZB subtype (GNA13/RHOA-enriched) | n=80




B. Duke 2017: Pan-DLBCL

All COO subtypes | n=974




C. DFCI 2018: GCB-DLBCL

Sample-level mutations | n=21



D. Odds Ratios for Late-Stage Disease

Reference: No pathway mutation / Non-EZB



Pathway ● Egress ● Retention ● Retention (proxy) p < 0.05 ○ FALSE ● TRUE

Retention pathway: GNA13, RHOA, S1PR2, P2RY8, ARHGEF1 | Egress pathway: GNAI2, CXCR4, S1PR1
EZB genetic subtype used as proxy for retention pathway mutations (Schmitz). Filled circles = p<0.05; Open circles = NS